SBIR/STTR Research Award
APC SPECIFIC MTOP INHIBITION POTENTIATES IMMUNE RESPONSE TO IIV IN ELDERLY RECIPIENTS.
Award amount
$597,638Program and phase
SBIR · Phase IAward year
2022Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Qrono, Inc.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- S8NSYCMSNF79
- Solicitation number
- PHS-2021-1
- Topic code
- 91
Research abstract
The contract supports the development of a vaccine adjuvant. The adjuvant development activities will occur within the context of an influenza vaccine.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Restoring Tolerance in Inflammatory Bowel Disease with an Oral AMPK agonist Nanomedicine that Targets Antigen Presenting Cells.
- Restoring Tolerance with an Oral AMPK Agonist Nanomedicine Targeting Intestinal Dendritic Cells as a Preventative Therapy for Type 1 Diabetes
- SCREENING FOR TOLEROGENIC ADJUVANTS TO ENHANCE ANTIGEN SPECIFIC IMMUNOTHERAPY FOR CELIAC DISEASE.
- IGF OT IGF FAILED TUBULIN INHIBITOR REFORMULATED AS LOCALIZED ADJUVANT THERAPY FOR HEAD AND NECK CANCER
- Computationally designed adjuvant platform enhancing dengue vaccine immunogenicity
Research funding history
10 SBIR/STTR records share this UEI (2013–2024). Reported award amounts total $5,289,085. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services, Department of Defense